Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrochemotherapy in Stage III Pancreatic Adenocarcinoma
NCT02514421Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Jul 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by UTHealth Houston. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Jul 2015; status: completed.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02514421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02514421.